Clinical trial OPT-PEMBRO
OPTimizing adjuvant prescription of PEMBROlizumab in patients with early-stage triple-negative breast cancer achieving pathologic complete response after standard neoadjuvant chemotherapy and pembrolizumab
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Oui |
| Sponsor | Unicancer |
| EudraCT Identifier | 2024-515787-31-00 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT06606730 |
| Last update |